Disease-modifying therapy for multiple sclerosis

PERSPECTIVES

TRYGVE HOLMØY

Trygve Holmøy, senior consultant, head of the Neuroimmunology Section at Akershus University Hospital and professor at the University of Oslo. Dr Holmøy heads the reference group of the Norwegian Multiple Sclerosis Competence Centre and has contributed as a medical expert to the Norwegian Institute of Public Health’s evaluation of methods for treating multiple sclerosis. He is also on the steering committee of the ENSEMBLE study. The author has completed the ICMJE form and reports the following conflicts of interest: He has received honoraria for lectures from Merck, Biogen, Genzyme, Sanofi, Novartis and Roche, and has taken part in treatment studies organised by Biogen, Merck and Roche. He is a member of the Norwegian MS Association’s medical committee and of the Pharmaceutical Purchasing Cooperation’s MS specialist team. He was a member of the working party that drew up the national guidelines for the diagnosis and treatment of multiple sclerosis.

GRO OWREN NYGAARD

Gro Owren Nygaard, senior consultant with the Department of Neurology, Oslo University Hospital, project manager for the NOR-MS clinical study. The author has completed the ICMJE form and reports the following conflicts of interest: She is a member of the Oslo MS research group and of the Norwegian Hospital Procurement Trust’s LIS-MS specialist team.

KJELL-MORTEN MYHR

Kjell-Morten Myhr, professor at the University of Bergen and senior consultant at the Department of Neurology, Haukeland University Hospital. He also heads the Neuro-SysMed centre, a research centre for clinical treatment of serious diseases of the central nervous system, including multiple sclerosis. The author has completed the ICMJE form and reports the following conflicts of interest: He has received honoraria for lectures from Biogen, Genzyme, Merck, Novartis and Roche, and has taken part in treatment studies organised by Biogen, Merck, Novartis and Roche. Myhr is a member of the Norwegian MS Association’s medical committee and of the Norwegian Hospital Procurement Trust’s MS specialist team. He also headed the working party that drew up the national guidelines for the diagnosis and treatment of multiple sclerosis.

LARS BØ

Lars Bø is director of the Norwegian Multiple Sclerosis Competence Centre, a senior consultant with the Department of Neurology, Haukeland University Hospital, and a professor at the University of Bergen. He is also coordinating investigator for the RAM-MS and SMART-MS clinical studies. The author has completed the ICMJE form and reports the following conflicts of interest: He has received honoraria for expert witness statements from the pharmaceutical company Synthon/Advokatfirmaet Kvale AS and honoraria for lectures from Roche. He has taken part in clinical studies organised by Genzyme, and is a member of the Norwegian MS Association’s medical committee and of the Norwegian Hospital Procurement Trust’s MS specialist team. He was a member of the working party that drew up the national guidelines for the diagnosis and treatment of multiple sclerosis.

High-efficacy therapy from the time of diagnosis substantially improves the prognosis for multiple sclerosis. The national guidelines on MS nevertheless recommend less effective therapy for many patients, and must be updated in pace with medical advances. We consider in the following how multiple sclerosis should be treated.

In multiple sclerosis (MS), the immune system attacks the central nervous system through lymphocytes initiating local inflammation. Clinically this gives rise to fully or partly transient neurological deficits, known as relapsing-remitting multiple sclerosis (RRMS). If untreated, the relapses convert to gradually increasing functional deficits, termed secondary progressive disease, when the neurodegeneration is no longer driven by lymphocyte attacks.

Disease-modifying MS therapy suppresses lymphocyte attacks. The effect is pronounced early in the course of the disease, and abates with the development of progressive disease (1). Early, high-efficacy therapy for relapsing-remitting multiple sclerosis slows the advance of progressive functional impairment in the majority of patients (2). Conversely, a more defensive escalation strategy, with gradually increasing therapeutic intensity, leads to progressive functional decline in the majority (3). This therapeutic principle used to be the dominant one (4), and is partly supported by the national guidelines on MS, which several of the authors were involved in drawing up in 2017 (5).

Therapeutic effects
The effect of relevant drugs on relapse frequency is shown in Table 1 (6–9). Owing to variation in the comparator and disease activity prior to the start of the study, it is not clear which drug is the most effective. Network-based analyses, as in the Norwegian Institute of Public Health's method evaluation of 2019, may shed light on this (10), but are usually based on short studies of selected patients. Real-world registry-based studies with long follow-up times provide clinically relevant evidence of long-term therapeutic efficacy and risk (11).

### Table 1

<table>
<thead>
<tr>
<th>Drug</th>
<th>Reduction of relapses in phase III trials (%)</th>
<th>Administration</th>
<th>Relevant comorbidity</th>
<th>Appropriate for those wanting children (7, 8)</th>
<th>Approved indication</th>
<th>Approved by Decision Forum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alemtuzumab</td>
<td>50–54 % vs interferon beta</td>
<td>Intravenously annually for two years</td>
<td>Immunodeficiency, Vascular disease, Autoimmunity</td>
<td>Partial</td>
<td>Probably transient</td>
<td>Very active RRMS</td>
</tr>
<tr>
<td>Ocrelizumab</td>
<td>46–47 % vs interferon beta</td>
<td>Intravenously monthly</td>
<td>Immunodeficiency</td>
<td>Yes</td>
<td>Yes</td>
<td>RRMS and PPMS</td>
</tr>
<tr>
<td>Ofatumumab</td>
<td>50–60 % vs teriflunomide</td>
<td>Subcutaneously monthly</td>
<td>Immunodeficiency</td>
<td>No</td>
<td>Probably yes</td>
<td>RRMS</td>
</tr>
<tr>
<td>Rituximab</td>
<td>Not conducted</td>
<td>Intravenously semi-annually</td>
<td>Immunodeficiency</td>
<td>Yes</td>
<td>Yes</td>
<td>Not applied for</td>
</tr>
<tr>
<td>Natalizumab</td>
<td>68 % vs placebo</td>
<td>Intravenously monthly</td>
<td>JCV carrier</td>
<td>Partial</td>
<td>No</td>
<td>Very active RRMS</td>
</tr>
<tr>
<td>Cladribine</td>
<td>55 % vs placebo</td>
<td>By mouth annually for two years</td>
<td>Immunodeficiency</td>
<td>Yes</td>
<td>Unknown</td>
<td>Highly active RRMS</td>
</tr>
<tr>
<td>Fingolimod</td>
<td>42 % and 52 % vs placebo 52 % vs interferon-beta</td>
<td>By mouth daily</td>
<td>Immunodeficiency</td>
<td>No</td>
<td>Yes</td>
<td>Highly active RRMS, also children</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Drug</th>
<th>Reduction of relapses in phase III trials (%)</th>
<th>Administration</th>
<th>Relevant comorbidity</th>
<th>Appropriate when wanting children (18, 19)</th>
<th>Significant reduction in response to vaccine (20)</th>
<th>Approved indication</th>
<th>Approved by decision-making forum</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ozanimod</td>
<td>39 % and 49 % vs interferon beta</td>
<td>By mouth daily</td>
<td>Immunodeficiency, Hypertension, AV block</td>
<td>No</td>
<td>Probably yes</td>
<td>Active RRMS</td>
<td>Yes</td>
</tr>
<tr>
<td>Dimethyl fumarate</td>
<td>44–53 % vs placebo</td>
<td>By mouth daily</td>
<td>Immunodeficiency, Effect on psoriasis</td>
<td>No</td>
<td>No</td>
<td>RRMS</td>
<td>Yes</td>
</tr>
<tr>
<td>Teriflunomide</td>
<td>32 % vs placebo 18 % vs interferon beta</td>
<td>By mouth daily</td>
<td>Immunodeficiency, Hypertension, Liver disease</td>
<td>No</td>
<td>No</td>
<td>RRMS</td>
<td>Yes</td>
</tr>
<tr>
<td>Interferon-beta</td>
<td>19–32 % vs placebo</td>
<td>Self-injection every 2 to 14 days</td>
<td>Depression</td>
<td>Yes</td>
<td>No</td>
<td>RRMS, CIS, SPMS</td>
<td>Yes</td>
</tr>
<tr>
<td>Glatirameracetate</td>
<td>29–34 % vs placebo</td>
<td>Self-injection from daily to 3 x weekly</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>RRMS</td>
<td>Yes</td>
</tr>
</tbody>
</table>

1Because of its adverse effects profile, the Pharmaceutical Purchasing Cooperation's specialist team does not class alemtuzumab on the same level as other MS therapy.
Both network-based analyses and longitudinal studies indicate that natalizumab, alemtuzumab, ocrelizumab and ofatumumab are among the most effective drugs. Phase II trials with frequent MRI scans also show them to have a rapid onset of action (11). Cladribine, fingolimod and ozanimod are also more effective than the first-line drugs interferon beta, glatiramer acetate and teriflunomide (11).

In the absence of phase III trials, longitudinal studies and phase II trials form the evidence base for the use of rituximab for multiple sclerosis (12). Like ocrelizumab and ofatumumab, rituximab is a monoclonal antibody that kills B-lymphocytes. Rituximab is more immunogenic, but except in rare cases of serum sickness, the significance of this is uncertain (13).

The long-term effect on the development of disability is more important than the relapse frequency, but more difficult to establish because the pivotal studies only last for two years. However, registry-based and follow-up studies show that the effect on relapses corresponds to the effect on the development of disability (2, 3). Studies of brain atrophy and biomarkers for neuronal injury support this (14). An overall assessment indicates that natalizumab, alemtuzumab, ocrelizumab, ofatumumab, rituximab, cladribine, fingolimod and ozanimod are highly effective for RRMS.

**Risk stratification**

High-efficacy drugs are generally tolerated better than less effective drugs, but may entail greater risk. Alemtuzumab stands out in that almost half of patients develop Grave’s disease or another autoimmune disorder. Moreover, opportunistic infections and acute angiopathy have caused deaths a short time after treatment (15). The Norwegian Hospital Procurement Trust’s specialist team therefore does not class alemtuzumab with other MS treatment.

Natalizumab can cause progressive multifocal leukoencephalopathy (PML) in carriers of JC virus. Other high-efficacy MS drugs, not least rituximab and ocrelizumab, reduce response to vaccines and increase the risk of infections (16).

«The possibility of risk stratification has now substantially reduced the risk associated with high-efficacy treatments»

The risk of progressive multifocal leukoencephalopathy in connection with natalizumab can be almost eliminated by not treating carriers of JC virus, and is substantially reduced for others by increasing the intervals between infusions (17). The risk associated with the other drugs can be reduced by taking comorbidity into account when selecting drugs (Table 1).

None of the MS drugs appear to appreciably increase the risk of COVID-19 infection. In registry-based studies, rituximab and ocrelizumab are associated with an increased need for intensive care and ventilation, but not with increased mortality (18).

**Treatment strategies**

When the association between natalizumab and progressive multifocal leukoencephalopathy was revealed in 2006, at-risk patients could not be identified. The escalation strategy was then justified on the basis of the precautionary principle. The possibility of risk stratification has now substantially reduced the risk associated with high-efficacy treatment. Clinical experience also indicates that less effective treatment is often halted because of adverse effects or lack of efficacy. It takes several months for a new treatment to become fully effective. Patients age and undergo more inflammatory episodes, and are at increased risk of complications and reduced efficacy by the time high-efficacy treatment is finally initiated.

An alternative strategy is to recommend high-efficacy treatment if prognostic factors such as relapse rate, number of lesions detected by MRI and involvement of the brainstem and spinal cord indicate a severe course. Such factors largely reflect previous disease activity. Even if they predict the prognosis at group level, it is uncertain whether they predict treatment benefit at the individual level. The long-term prognosis at the time of diagnosis is normally so uncertain that prognostic factors do not justify starting less effective treatment.

Pivotal studies, longitudinal studies and effect on biomarkers all indicate that early treatment with high-efficacy agents results in the greatest benefit and least risk over time (2, 3, 19, 20). As a general rule we therefore recommend immediate initiation of high-efficacy drugs in cases of RRMS (Figure 1). Potential exceptions are patients who for reasons of age or comorbidity are particularly vulnerable to harmful treatment effects (Table 1), or where many years of observation since symptom onset point to a benign disease course.
Figure 1: Flow chart for choice of treatment of relapsing-remitting multiple sclerosis (RRMS). Decisions relating to therapy are taken in consultation with the patient according to individually tailored information. As a general rule, patients with recently diagnosed RRMS should be offered high-efficacy treatment with natalizumab, ocrelizumab, ofatumumab, rituximab, cladribine, fingolimod or ozanimod. Factors with a bearing on the choice of these drugs are shown in the box on the right. In the event of significant disease activity in the form of relapse or MRI activity, more effective therapy should be considered if possible. A change of medication will not necessarily improve disease control in patients who are already using a high-efficacy drug. On the contrary, switching from natalizumab, fingolimod or ozanimod to other therapy may trigger rebound disease activity. Changes in therapy must therefore be thoroughly considered and planned, and ongoing treatment must not be discontinued before the time of starting new treatment is known.

Choice of high-efficacy drug

The differences in efficacy, risk and other treatment-related burden among most high-efficacy drugs are uncertain. The choice of drug therefore tends to depend on other factors (Table 1).

In cases of pronounced inflammatory activity, we recommend drugs with a fast onset effect, such as natalizumab, ocrelizumab and rituximab.

Multiple sclerosis often affects young women. Many pregnancies are not planned, and changes in treatment increase the risk of disease activity. Fertile women should therefore be offered treatment that makes pregnancy possible without a break in treatment.

The effects of cladribine, ocrelizumab and rituximab last long after they have been eliminated from the body, and they are therefore suitable for fertile women. Alemtuzumab has the same property, but the risk of Grave’s disease means that close monitoring is required during pregnancy. Natalizumab can be used up to the last trimester. Breaks in treatment may cause severe disease breakthrough nonetheless. Fingolimod and ozanimod are probably teratogenic, and breaks in treatment may result in severe disease flare-ups. They are therefore less suitable for fertile women.
Comorbidity such as immunodeficiency, chronic infections, liver disease, cardiovascular disease, hypertension and uveitis influence the choice of therapy (Table 1). Natalizumab results in limited immunosuppression and may be suitable for patients with immunodeficiency or chronic infections. Some MS drugs are also effective against other diseases; for instance, natalizumab and ozanimod are effective against inflammatory bowel disease and dimethyl fumarate is effective against psoriasis.

**Discontinuing treatment**

In the past it has been usual to discontinue immunomodulatory treatment after transition to secondary progressive disease. However, with high-efficacy treatment it is difficult to know whether patients with slow progressive functional decline still have latent RR disease.

Discontinuation of natalizumab, fingolimod and ozanimod is associated with a substantial risk of serious relapses, and great caution should therefore be exercised when discontinuing these drugs. On the other hand, the risks associated with immunosuppression increase with age, and approved dosage is based on studies of patients under the age of 60. Observational studies indicate that the effects of natalizumab and rituximab remain the same when interdose intervals are increased (13, 21) but there is a general lack of reliable evidence as to when and how immunomodulatory treatment should be tapered, and patients must always be monitored clinically and radiologically.

As alemtuzumab and cladribine are not usually redosed, the question of discontinuation of treatment is avoided.

**Haematopoietic stem cell transplantation**

In open-label studies, high-dose chemotherapy with autologous haematopoietic stem cell transplantation reduces disease activity in RRMM very effectively (22). The risk of serious complications is low in younger patients who are otherwise healthy. In Norway, the treatment is offered at Haukeland University Hospital on strict indication, mainly as part of a randomised trial. The treatment may be relevant for more patients in the future.

**Progressive multiple sclerosis**

Phase III trials show that ocrelizumab and siponimod are moderately effective for primary and secondary progressive disease, primarily in patients with relapses or new MRI lesions (23). These drugs have not been approved by the Decision Forum. As their efficacy is probably due to suppression of lymphocyte attacks, we recommend attempting therapy with other high-efficacy drugs for younger patients with rapid clinical exacerbation, relapses or MRI activity.

**Financial and regulatory aspects**

Expenditure on MS drugs was almost a billion kroner in 2019 (Anne Helen Ognøy, Norwegian Hospital Procurement Trust, personal communication). The prices are negotiated by the Norwegian Hospital Procurement Trust and are exempt from public disclosure. Following a health economics assessment as part of the Norwegian Institute of Public Health’s method evaluation, the Decision Forum decided in 2019 to halt the start-up of fingolimod and natalizumab, although the costs did not differ from those of drugs the specialist community judges to be equivalent.

«Individually tailored high-efficacy treatment should be the general rule»

The Decision Forum also declined to introduce siponimod and ocrelizumab. They have subsequently rejected all applications from the specialist community for exceptions for subgroups of patients, but have introduced rituximab, which costs about a twentieth as much as ocrelizumab. In 2019 rituximab was the drug most widely used in Norway for multiple sclerosis (8). Large regional differences may reflect different attitudes to providing treatment outside of the approved indications and without the support of phase III trials. Comparative studies are now being conducted with ocrelizumab and cladribine. The approved indication for other high-efficacy MS drugs is generally narrower than that applied in clinical practice (Table 1). Thus treatment outside of an approved indication is widespread and increasing.

**CONCLUSION**

Swift and effective treatment of relapsing-remitting multiple sclerosis substantially improves the prognosis. Individually adapted high-efficacy treatment should be the general rule. The national guidelines on MS must be revised continuously in pace with developments in the discipline.

**LITERATURE**

